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Prognostic models are abundant in the medical literature yet their use in
practice seems limited. In this article, the third in the PROGRESS
series, the authors review how such models are developed and validated,
and then address how prognostic models are assessed for their impact on
practice and patient outcomes, illustrating these ideas with examples.
The first two papers in this series focus on the variability in
prognostic endpoints given specific startpoints [1] and on the search
for factors that are associated with these endpoints [2]. Adequate
prediction of prognostic endpoints, however, generally requires
multiple prognostic factors (variables, predictors, or markers).
A prognostic model is a formal combination of multiple predictors
from which risks of a specific endpoint can be calculated for individual
patients. Other names for a prognostic model include prognostic (or
prediction) index or rule, risk (or clinical) prediction model, and
predictive model. For an individual with a given state of health
(startpoint), a prognostic model converts the combination of predictor
values to an estimate of the risk of experiencing a specific endpoint
within a specific period. Ideally this produces an estimate of the absolute
risk (absolute probability) of experiencing the endpoint, but it may
instead provide a relative risk or risk score [3–5]. A well known, simple
example is the Nottingham Prognostic Index (see Box 1) [6], which
gives a score that relates to the survival probability of a woman with
newly diagnosed breast cancer based on a combination of tumour
grade, number of involved lymph nodes, and tumour size. Survival
curves can be plotted for risk groups derived from the model, analogous
to those for different values of a single prognostic factor shown in paper
2 of this series [2]. Figure 1 shows such curves for four risk groups
derived from a prognosticmodel for renal outcome in IgA nephropathy.
Such separation into risk groups is visually pleasing but disguises the
large variation across groups in the actual event times of individuals.
Using prognostic models to make predictions for individual patients is
more accurate and so is often preferred to risk grouping, although risk
groups may inform treatment choices and enable stratification for risk
severity in clinical trials. Some prognostic models are accessible as web
tools. For example, Figure 2 shows the predicted probability of death
within 14 days and of death or severe disability at six months for a
specific patient admitted to hospital with traumatic brain injury [7].
Aims of This Paper
In a previous BMJ series [4,8–10] we described methods of
developing a prognostic model, its external validation in a new
setting, and evaluation of its clinical impact. We here discuss
potential bottlenecks in these stages of evaluation to ensure that
good prognostic models become clinically useful. We provide
illustrative examples from oncology, cardiovascular disease,
musculoskeletal disorders, and trauma (Table 1). We also consider
the desirability of improving an existing model by incorporating
novel prognostic factors or (bio)markers [11–13].
We present findings of a systematic review of six leading general
medical journals to obtain information about the number and
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nature of publications in 2006–09 reporting the development,
validation, or assessment of impact of a prognostic model (see Text
S1). Prognostic models are abundant in the medical literature [14–
17], but few of the models are implemented or used in clinical
practice [18]. Worse still, few models are evaluated for their
impact on health outcomes, as shown in Figure 3.
Why Are Prognostic Models Important?
Prognostic models are important at different stages in pathways
leading to improvements in health (Figure 3, lower panel). The use
of prognostic models ties in with the strong movement towards
stratified medicine, where decisions regarding treatment choices
are informed by an individual’s profile of prognostic factors.
Prognostic models aim to assist (not replace) clinicians with their
prediction of a patient’s future outcome and to enhance informed
decision making with the patient.
The results from randomised therapeutic trials can be used to
estimate how a specific treatment would modify a patient’s
estimated prognosis. Under the common assumption that a
particular treatment has a constant relative benefit across all risk
groups, the absolute treatment benefit depends on a person’s
predicted risk of the outcome without treatment [19]. Expensive
therapies or those with harmful potential side effects may thus be
reserved for those at higher risk, as estimated by a prognostic model.
Some prognostic models are used in clinical practice without
being identified as such, such as the Apgar score for assessing the
wellbeing of newborn babies [24]. Other examples of well used
prognostic models include the Nottingham Prognostic Index [6],
the O¨rebro Musculoskeletal Pain Screening Questionnaire to help
clinicians identify patients with low back pain at risk of poor
recovery [20], and the Manchester Triage System to assign
priority based on clinical need among patients visiting an
emergency department [21] (see Table 1). A prognostic model
can thus be seen as an intervention that requires preclinical
development, validation, and subsequent evaluation of its impact
on health outcomes and cost effectiveness of care.
Prognostic models are also important to help improve the design
and analysis of randomised therapeutic trials [22,23], and to adjust
for case mix variation in health services research [24], such as in
understanding variations in patients’ outcome across hospitals
[25].
Key Steps to Making Prognostic Models Useful
Developing a Good Prognostic Model
The decision to develop a new prognostic model will be stimulated
by a specific clinical uncertainty. Essential components are the
startpoint and the specific outcome (endpoint). Methods for developing
models have been widely discussed [3,5,10] andwill not be described in
detail here. In brief, prognostic models are usually and perhaps ideally
derived with multivariable regression techniques on data from
(prospective) cohort studies. Logistic and Cox regression modelling
are most often used for short term and long term dichotomous
outcomes (event occurrence yes/no) respectively. Important issues to
be addressed include dealing with missing data [26], modelling
continuous prognostic factors [27,28], the complexity of the model
[29], and checking the model assumptions. An important aim is to
avoid statistical overfitting, especially when selecting from many
candidate prognostic factors in a relatively small dataset.
Summary Points
N The PROGRESS series (http://www.progress-partnership.
org) sets out a framework of four interlinked prognosis
research themes and provides examples from several
disease fields to show why evidence from prognosis
research is crucial to inform all points in the translation of
biomedical and health related research into better patient
outcomes. Recommendations are made in each of the four
papers to improve current research standards.
N What is prognosis research? Prognosis research seeks to
understand and improve future outcomes in people with a
given disease or health condition. However, there is
increasing evidence that prognosis research standards
need to be improved.
N Why is prognosis research important? More people now
live with disease and conditions that impair health than at
any other time in history; prognosis research provides
crucial evidence for translating findings from the labora-
tory to humans, and from clinical research to clinical
practice.
N Prognostic models use multiple prognostic factors in
combination to predict the risk of future clinical outcomes
in individual patients. A useful model provides accurate
predictions that inform patients and their care givers,
supports clinical research, and allows for informed
decisions to improve patient outcomes.
N Prognostic model research has three main phases: model
development (including internal validation), external vali-
dation, and investigations of impact in clinical practice.
Although many prognostic models are proposed, relatively
few are currently used in clinical practice.
N Most publications on prognostic models describe model
development, a small number report external validation
studies, and only very few consider clinical impact or
usefulness.
N Reliable models for clinical practice are more likely to be
obtained when they are:
˚
Developed using a large, high quality dataset
˚
Based on a study protocol with a sound statistical
analysis plan
˚
Validated in independent datasets obtained from
different locations
N When accurate prognostic models are identified, impact
studies are required to investigate their influence on
decision making, patient outcomes, and costs.
N The performance of prognostic models may wane over
time, possibly as diagnosis or treatments change. Rather
than always developing new models from scratch, research-
ers should consider whether existing models can be
improved by recalibration or adding novel predictors
such as new biomarkers or results from new imaging
techniques.
N The other papers in the series are:
˚
PROGRESS 1: BMJ 2013, doi:10.1136/bmj.e5595
˚
PROGRESS 2: PLOS Med 2013, doi:10.1371/jour-
nal.pmed.1001380
˚
PROGRESS 4: BMJ 2013, doi:10.1136/bmj.e5793
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Before any prognostic model might be adopted in practice it is
necessary to show that it provides predictions that are valid outside
the specific context of the sample that was used for model
development (external validation) and ideally has real clinical
impact. Of 86 papers published in leading general medical
journals in 2006–09 that reported studies of prognostic models, the
vast majority (n = 61) described the development of a prognostic
model. The dearth of external validity and impact studies indicates
no sign of improvement over earlier, similar reviews (see Figure 3
and Text S1).
Validating a Prognostic Model
The predictive performance of a model estimated on the
development data is often optimistic, related to multiple testing
with a limited sample size [3,5,30,31]. A newly developed
prognostic model needs to be validated with patient data not
used in the development process and preferably selected from
different settings (external validation) [8,32–34]. Indeed, the
performance in such a validation study is arguably all that
matters, and how a model was derived is of little importance if it
performs well. Validation studies provide estimates of a model’s
ability to discriminate between patients with different outcomes
and of the agreement between predicted and observed risks [35].
Our review found 21 publications which described external
validation of a prognostic model (Figure 3 and Text S1). Among
these, 18 included a geographical external validation (that is,
validity of predictions for patients in another geographical area)
and three a temporal external validation (validity in the same
location at a later time) [32]. Validation of a prognostic model in a
random part of the development cohort was common (14 of the 61
development studies). However, this approach (commonly referred
to as internal validation) is statistically inefficient and methodo-
logically weak since no difference in time or place exists other than
by chance [8,36].
For the Nottingham Prognostic Index, predictive performance
has been tested in many external, often large, validation studies
[37]. The O¨rebro Musculoskeletal Pain Screening Questionnaire
[20] has been validated in several independent patient samples by
multiple research groups, with 11 external validation studies up to
2009 (Table 1).
Evaluating the Impact of a Prognostic Model on Clinical
Practice and Outcomes
A prognostic model can influence patient outcome or the cost
effectiveness of care only when changes in clinical management
are made based on the prognostic information provided [9,33].
Prognostic models have a cost in their implementation and might
even have adverse consequences on clinical outcomes if they lead
to decisions that withhold beneficial treatments (such as from
people deemed by the model to be at low risk). Convincing
evidence for the impact, positive or negative, of using prognostic
models on patient outcome is hard to come by [9]. Our systematic
review identified only two published analyses of the impact of
prognostic models (Figure 3 and Text S1). A failure to recognise
prognostic models as health technologies may be one reason why
impact studies are lacking.
Most prognostic models are developed and validated with data
from a single cohort of patients. Assessment of the impact of a
model on decision making and patient outcome requires a
comparative study [9,33]. Here two groups (cohorts) need to be
compared, one in which usual care is provided without the use of
the model and another group in which model predictions are
made available to doctors and other health professionals to guide
treatment decisions. This comparison is scientifically strongest in a
(cluster) randomised trial. An example is the STarTBack trial, in
which primary care patients with back pain were randomised to
receive either stratified care based on their risk of future disability
or non-stratified best care. The results showed a significantly larger
reduction in disability as well as cost savings in the group receiving
stratified care compared with the control group [38].
Randomised trials are expensive and time consuming, and other
approaches are possible. One can compare clinicians’ decision
making and patient outcomes observed in a time period before a
model was introduced versus a time after it became available. An
example of such a before and after study is an investigation of the
effect of using the Nottingham Prognostic Index on the decision to
treat women with adjuvant chemotherapy, resulting in modest effects
on survival after its implementation [39]. However, potential time
effects such as changes in current treatments should always be
considered [9]. It is therefore desirable to include control practices
that continue to deliver usual care in the time after implementation.
Alternative designs are necessary when there is a long time lag
between the moment of prognostication (use of the model) and
patient outcome or when outcomes are relatively rare. First, if a
model has been well developed and validated, decision analytical
Box 1. The Nottingham Prognostic Index (NPI)
[6]
The NPI combines tumour size, whether the cancer has
spread to the lymph nodes, and the grade of the cancer to
produce a risk score for women with newly diagnosed
breast cancer. The formula is
NPI~ 0:2|tumour diameter cmð Þð Þz
lymph node stageztumour grade
where:
Lymph node stage is scored as 1 (no nodes affected), 2 (#3
glands affected), or 3 (.3 glands affected).
Tumour grade is scored as 1, 2, or 3.
A lower score suggests a good outcome.
Figure 1. Kaplan-Meier survival curves for four risk groups
derived from a prognostic model that provides a score to
predict renal outcome in IgA nephropathy (reproduced from
Goto et al [83]).
doi:10.1371/journal.pmed.1001381.g001
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modelling can be used to combine information on model
predictions with information about the effectiveness of treatments
from randomised trials or meta-analyses. If such modelling does
not indicate improved outcome or favourable cost effectiveness, a
long term randomised impact study may not (yet) be warranted.
An example is a modelling study on the cost effectiveness of using
various risk scores (with and without novel biomarkers) in patients
with stable angina [40]. This study found that prioritising coronary
surgery according to a prognostic model based on simple, readily
available biomarkers was likely to be cost effective.
Another option is a cross sectional study with physicians’ decisions
as primary outcome [9,41]. Clinicians or patients are randomised to
either have or not have access to predictions from the prognostic
model, and their therapeutic or other management decisions are
compared. In another design, clinicians can be asked to decide on
treatment or patient management before and after being provided
with a model’s predicted probabilities. This design has been used to
assess the effect of using an additional test on medical decision
making, such as 18-fluoro-deoxyglucose positron emission tomogra-
phy (FDG-PET) to guide decisions on brain surgery [42].
For traumatic brain injury, no study has evaluated clinical
impact, although many claim that the predictions from the models
can be used to inform patients and relatives regarding prognosis.
The CRASH and IMPACT models [7,43] were based on large
numbers of patients (n = 10 008 for CRASH, n= 8535 for
IMPACT) and were well validated, but their application lies
predominantly in research [44], in particular the design and
analysis of randomised trials [23]. Impact on decision making for
individual patients is less likely since predictions are not sufficiently
certain to guide treatment limiting decisions [45].
The use and potential impact of prognostic models may be
reflected in citations in practice guidelines and websites. That is
the case for the Nottingham Prognostic Index, which is widely
cited and included in the National Institute for Health and Clinical
Excellence (NICE) guidelines of 2009 (Table 1). The evidence for
its impact is still scarce, however. The use of O¨rebro Musculo-
skeletal Pain Screening Questionnaire is recommended in several
clinical practice guidelines and on several websites (such as Work
Cover Australia (http://www.workcover.nsw.gov.au) and the
Australia Transport Accident Commission (http://www.tac.vic.
gov.au)). Again, empirical evidence of its impact on physicians’
decision making, let alone patient outcomes, is lacking.
Updating a Prognostic Model
Updating a model is often desirable [5,9,46–48]. In particular,
some systematic miscalibration is common for predictions
obtained from prognostic models in settings that differ from that
of the development sample. Updating methods include recalibrat-
ing the model to the new setting or investigating the addition of
new prognostic factors, including biomarkers, to an existing model
[46]. Ideally there should be an ongoing process of model
validation and updating [5,9,46–48].
The contribution of genomic, proteomic, or metabolomic
measures and new imaging tests over and above established
prognostic factors is a key issue in current prognostic research
[41,49]. For example, a simple model for patients with traumatic
brain injury that included just three strong prognostic factors was
extended with computed tomography results in a second stage,
and laboratory test results in a third stage [43]. The more
extended models yielded more refined predictions and better
discrimination. Various novel markers have been considered for
their potential to improve the Nottingham Prognostic Index
(Table 1).
The importance of assessing the impact of new markers on the
accuracy of a model is widely agreed, but how best to quantify any
changes in prediction is an active topic of methodological research
[11–13]. The recent trend when comparing models is to consider
the extent of reclassification of individual patients between risk
groups rather than using global measures of discrimination such as
the area under a receiver operating characteristic (ROC) curve
[12,50]. These different statistics are mathematically related,
however [51,52].
The addition of new markers may yield only marginal benefit
[53]. Because standard models generally include important
predictors, the independent effects of new prognostic factors need
to be quite strong before a clinically useful improvement is
achieved [54]. For example, adding two markers to a prediction
model for patients with heart failure led to 342 (15%) of the 2345
patients initially classified as having a ,10% probability of dying
within 1 year being reclassified as .10% probability. In addition,
345 (29%) of the 1206 patients initially classified as having a
$10% probability of dying within 1 year were reclassified as
having ,10% probability (Table 2) [55]. Furthermore the
measurement of new markers carries cost implications [41].
A particular motivation to update a prognostic model is to
replace existing predictors that suffer from substantial inter-
observer variability (such as physical examination, imaging, and
histopathological techniques) [56] with more reliably measured
markers. Moreover, prognostic models that include factors or
markers with a causal effect on the outcome under study may be
expected to be more generalisable to other populations. Such
models may also be better used, since they are linked to biological
(or other) pathways rather than merely based on statistical
association [8]. While these suggestions are plausible, empirical
evidence is lacking.
Clinical Use of Prognostic Models
The clinical use of prognostic models should be dependent on
evidence of successful validation and, preferably, on evidence of
clinical impact when using the model. Not all of the models
mentioned above followed this path. For example, the predictors
Figure 2. Web tool for prognosis of patients with head injury
(CRASH trial) (reproduced from Perel et al [7] with permission).
doi:10.1371/journal.pmed.1001381.g002
PLOS Medicine | www.plosmedicine.org 4 February 2013 | Volume 10 | Issue 2 | e1001381
and their weights included in the Manchester Triage System [21]
were developed by medical experts without statistical modelling of
patient data. It was motivated by emergency department
crowding, and the aim was to shorten waiting times for those
presenting with high urgency. Shortly after its development, the
Manchester Triage System was introduced in various emergency
departments. The Manchester Triage System is currently imple-
mented throughout Europe. Still only limited validation studies
have been performed and no impact studies. Early evaluations
have focused on inter-observer agreement [57] rather than on a
validation of its predictive performance [58].
One key factor for successful implementation of a prognostic
model seems to be whether a model is supported by leading
professionals in the field of application. For example, many
prognostic models have been promoted for outcome prediction in
prostate cancer with direct involvement of leading clinical
Figure 3. Distribution of published articles describing model development, validation, and impact assessment in four reviews (see
Text S1). Path element adapted from Chart 7.1 in the Cooksey report (2006) http://bit.ly/Ro27rL (made available for use and re-use through the
Open Government License).
doi:10.1371/journal.pmed.1001381.g003
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investigators [18,59]. Also, prognostic factors generally need to be
readily available in routine care to allow for application of the
prognostic model. That necessity may form a barrier to the use of
relatively expensive or hard to access tests or new markers for
prediction in primary care.
Other factors that might be associated with use of prognostic models
in practice include the complexity of the model (a few or many
prognostic factors) [29], the format of the model (as a score chart on
paper, web based, or as standard part of an electronic patient record),
the use of cut-off values for model predictions to guide decision making
(rather than only providing the predicted probability), the ease of use in
the consulting room, the clinical context, and the fear of ‘‘cookbook
medicine’’ or medicolegal consequences of undue reliance on model
based predictions and decisions [9,33].
Recommendations for Improving Prognostic
Models Research
The number of published prognostic models is increasing.
Unfortunately, they are often developed from poor data, inappro-
priately analysed, and poorly reported. For example, 10 years ago a
review of 83 prognostic models in stroke found that most showed
high risk of bias and serious deficiencies in statistical methods, with
only four studies meeting eight simple quality criteria [14]. None
had been adequately validated. A recent review of 137 studies of 101
clinical prediction rules in children, most published after 2001,
showed similar methodological problems [60]. Only eight of the
rules for health conditions of childhood had undergone prospective
validation in broad or multiple settings. There were no impact
studies. Other reviews of prognosis models across many medical
areas have documented similar shortcomings [15,61–63].
Clearly standards must be raised. Many of the recommenda-
tions across the PROGRESS series are relevant (see supplemen-
tary table of PROGRESS recommendations, Table S1). Here we
highlight those recommendations particularly important for
prognostic models.
Clinical Impact Studies
To be useful for clinicians, a prognostic model needs to provide
validated and accurate predictions and to improve patient
outcomes and cost-effectiveness of care. There should be more
research into understanding the impact (clinical effectiveness and
Table 1. Examples of the development, validation, and impact of prognostic models.
Name of prognostic model Development Validation Impact
Nottingham Prognostic Index Survival in 387 women with
primary, operable breast
cancer [6,74]
Many studies, including an
external validation in 9149
Danish patients [75]
Cited in guidelines.
Survey indicated use in many centres to decide on
adjuvant chemotherapy [76].
Modelling study for cost effectiveness analysis
[76].
O¨rebro Musculoskeletal Pain
Screening Questionnaire
Acute and subacute back pain
in 142 workers [20]
At least 11 studies (median study
size 123, range 45–298) [77–79]
Cited in guidelines and websites [80,81].
Used to select trial participants [82].
CRASH/IMPACT 6 month outcome after traumatic
brain injury (n = 10 008 for CRASH,
n = 8530 for IMPACT) [43]
Cross-validation of CRASH on
IMPACT and vice versa [43]
Cited as source of prognostic risk estimation [7].
Used to select trial participants and in analysis
of randomised controlled trials.
Manchester Triage System Urgency classification system by
experts [21]
16 735 children in 2 Dutch
hospitals [58]
Widely cited in most Western guidelines.
Widely implemented, even before publication.
doi:10.1371/journal.pmed.1001381.t001
Table 2. Reclassification of patients into prognostic groups by adding two biomarkers (brain natriuretic peptide and serum
troponin T) to a prognostic model for patients with heart failure [55].
Model 1 (baseline assessments) Model 2 (baseline assessments+biomarkers)
Predicted probability ,10% Predicted probability $10% Total
Predicted probability ,10%:
No (%) of subjects 2003 (85) 342 (15) 2345
Observed dead (%) 4.4 12.3 5.6
Predicted dead, model 1 (%) 5.7 7.8 6.0
Predicted probability $10%:
No (%) of subjects 345 (29) 861 (71) 1206
Observed dead (%) 7.2 20.3 16.6
Predicted dead, model 1 (%) 13.0 16.9 15.8
Total:
No (%) of subjects 2348 (66) 1203 (34) 3551
Observed dead (%) 4.9 18.0 9.3
Predicted dead, model 2 (%) 5.0 17.8 —
doi:10.1371/journal.pmed.1001381.t002
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costs) of using prognostic models in real world clinical practice.
Clinical practice guideline recommendations relating to the use of
prognostic models should be based on such impact studies
(recommendation 19 in Table S1).
Clinical Use of Prognostic Models
Easily used prognostic models may be more likely to be
incorporated into clinical practice—examples include the Notting-
ham Prognostic Index [6], Framingham Risk Score [64], and
CHADS score [65]. Indeed, some easily used models have been
recommended for use without adequate evaluation. There should
be more research into why some models are prematurely
translated into clinical practice without adequate evaluation,
whereas other models with evidence of cost effectiveness are not
translated (recommendation 18).
Statistical Methods and Data Quality in Model
Development
Successful validation and clinical value are more likely when a
model is developed using sound statistical methods and adequate
data [3,5,27]. Published models have often been developed using
inferior statistical methods [8,15,46,61,66]. To enhance the
reliability of future models, studies should be sufficiently large
and based on a study protocol including a statistical analysis
plan,including careful attention to the handling of missing data
and continuous predictors (recommendation 13) [5,27,67]. Data
quality is a key aspect of developing a reliable model. Since
clinically collected data may contribute many or all of the variables
in a prognostic model, there should be a better understanding of
the influence of clinical measurement techniques and missing
observations on model performance (recommendation 20).
Validation of Prognostic Models
It is seldom (if ever) acceptable to publish the development of
a prognostic model without at least internal validation (such as
cross validation or bootstrapping). Claiming that a model is
clinically valuable is acceptable only with an external validation
study using independent data from a different location than the
development data (recommendation 9). Investigators should
more often evaluate the performance of a newly developed
model in a different physical location or clinical setting
(recommendation 9).
Collaboration between Research Groups
The collation and synthesis of individual participant data from
multiple studies offers a natural opportunity to increase sample size
[68]. Models can then be developed using data from a subset of
studies and assessed on data from the remaining studies. Variation
in model accuracy across studies and its causes can be explored.
Also, such collaborative efforts encourage consensus towards a
single well developed and validated prognostic model, rather than
a number of competing and non-validated models for the same
clinical problem championed by each group separately. Finally,
such unification may enhance the uptake of prognostic models in
practice. For example, the IMPACT consortium developed a
prognostic model for mortality and unfavourable outcome in
traumatic brain injury by sharing individual participant data from
11 studies (8509 patients), with successful external validation using
individual participant data from another large study (6681
patients, Table 1) [43]. We encourage researchers to support
collaborative efforts on data sharing to provide individual patient
data to enhance the development and validation of prognostic
models (recommendation 17).
Updating a Prognostic Model
The performance of prognostic models may wane over time (for
example, because diagnosis or treatments change). Also, new
markers may become available. Rather than always developing
new models from scratch, more often researchers should build on
existing work and consider whether existing models can be
improved by recalibration or adding new variables such as novel
biomarkers (recommendation 21) [5,9,46–48,69].
Quality of Reporting
Reviews have shown widespread deficiencies in publications
describing the development and validation of prognostic models
[15,61–63,70]. For example, many reports fail to indicate
adequately the performance of the model [62] and do not
present the results in a way that can be used by clinicians [15].
Better reporting of development and validation studies is needed
to help clinicians and other decision makers identify robust
models with potential clinical value (recommendation 15).
Consensus guidelines should be developed for reporting prog-
nostic model research (recommendation 15), and that process is
under way.
Conclusion
Prognostic model research has three main phases: model
development (including internal validation), external validation,
and investigations of impact on decision making and patient
outcomes [4,8–10,33]. Many prognostic models are used without
clear evidence of their impact, while other well developed and
validated models are not used at all. We encourage researchers to
support collaborative efforts to share individual patient data
allowing for both better model development and external
validation. Rather than developing a steady stream of new
prognostic models, researchers should shift to validation, updating,
and impact studies of existing models. In the present era of
biomarkers and ‘‘omics,’’ we encourage assessment of the extent to
which new markers add value to existing models.
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